T. Lyle

发表

Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

W. M. Sanders, T. Tucker, M. Goldman, 1994, Journal of Medicinal Chemistry.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

Carbon-13 nuclear magnetic resonance study of nucleophilic additions to benzo[a]pyrene-4,5-oxide and of its acid-catalyzed rearrangement

D. L. Jagt, T. Lyle, M. Hylarides, 1979 .

Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors.

W. M. Sanders, Youwei Yan, S. D. Lewis, 2003, Bioorganic & medicinal chemistry letters.

Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.

J. Vacca, J. Shafer, Z. Chen, 1998, Journal of medicinal chemistry.

Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.

M. Rudd, J. Vacca, N. Liverton, 2008, Angewandte Chemie.

Amino acid sequence of homologous rat atrial peptides: natriuretic activity of native and synthetic forms.

N. Seidah, R. Nutt, S. Brady, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues.

R. Nutt, S. Brady, E. Faison, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Glucagon releasing activity of a cyclic peptide related to somatostatin.

D. Veber, R. Freidinger, R. Nutt, 2009, International journal of peptide and protein research.

Structure-activity studies of atrial natriuretic factor

D. Veber, R. Nutt, S. Brady, 1988 .

Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.

Lawrence C Kuo, Berta Strulovici, Daniel R McMasters, 2005, Bioorganic & medicinal chemistry letters.

P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.

Youwei Yan, L. Kuo, J. Vacca, 2005, Bioorganic & medicinal chemistry letters.

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability.

J. Vacca, B. Wong, S. D. Lewis, 2004, Bioorganic & medicinal chemistry letters.

Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.

Youwei Yan, L. Kuo, J. Vacca, 2003, Bioorganic & medicinal chemistry letters.

Synthesis, evaluation, and crystallographic analysis of L-371,912: A potent and selective active-site thrombin inhibitor.

W. M. Sanders, R. Freidinger, S. Gardell, 1997 .

Small-molecule inhibitors of thrombin

T. Lyle, Terry A. Lyle, 1994 .

New Developments in HIV Therapeutics

Michael D. Miller, T. Lyle, 2005 .

Vinyl fluoride function as a terminator of biomimetic polyene cyclizations leading to steroids

M. Niwa, T. Lyle, W. S. Johnson, 1980 .

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.

Qian Huang, Adam T. Gates, M. Rudd, 2012, Bioorganic & medicinal chemistry letters.

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Daniel R McMasters, James C Barrow, W. M. Sanders, 2003, Journal of medicinal chemistry.

Photochemical reactions, 135th communication Photochemistry of Homoconjugated Cyclobutanones. II. Decisive Effect of gem‐ Dimethyl Substitution on the Course of the Oxa‐di‐π‐methane Rearrangement

T. Lyle, H. Mereyala, A. Pascual, 1984 .

Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.

Youwei Yan, J. Vacca, B. Wong, 2006, Bioorganic & medicinal chemistry.

Fluorescence lifetimes of several structurally rigid t-stilbene derivatives

C. Pyun, Su-Moon Park, T. Lyle, 1986 .

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold.

D. Hazuda, S. Venkatraman, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.

P. Anderson, J. Thies, W. J. Thompson, 1990, Journal of medicinal chemistry.

Fluoride-induced formation and ring opening of cyclic sulfamates from hydroxy triflamides: synthetic and mechanistic studies

T. Lyle, S. Pitzenberger, C. Magill, 1987 .

Synthesis of some tetrahydrochrysenes as potential ultraviolet laser dyes

T. Lyle, G. Daub, 1979 .

HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.

P. Darke, A. Deana, S. Graham, 1992, Journal of medicinal chemistry.

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

E A Emini, P. Anderson, P. Darke, 1991, Journal of medicinal chemistry.

Ribonucleic Acid Viruses: Antivirals for Human Immunodeficiency Virus

T. Lyle, 2007 .

3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors.

E A Emini, Arun K. Ghosh, P. Darke, 1993, Journal of medicinal chemistry.

Chemical synthesis of rat atrial natriuretic factor by fragment assembly on a solid support

D. Veber, R. Nutt, S. Brady, 1987 .

Reactivity-selectivity properties of reactions of carcinogenic electrophiles with biomolecules. Kinetics and products of the reaction of benzo[a]pyrenyl-6-methyl cation with nucleosides and deoxynucleosides

D. L. Jagt, G. Moy, T. Lyle, 1979 .

Structure-activity studies and antiviral properties of hydroxyethylene transition state inhibitors of HIV-1 protease

P. Anderson, P. Darke, W. Schleif, 1992 .

Photochemical Reactions. 125th communication [1]. Photochemistry of homoconjugated cyclobutanones. I. Synthesis and photolysis of a Spiro [3.6]deca‐5, 7‐dien‐1‐one

T. Lyle, B. Frei, 1981 .

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

D. Hazuda, W. Schleif, L. Gabryelski, 2008, Bioorganic & medicinal chemistry letters.

Kilogram Scale Synthesis of the Pyrazinone Acetic Acid Core of an Orally Efficacious Thrombin Inhibitor

J. Armstrong, F. Fleitz, R. Volante, 2000 .

8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors.

D. Hazuda, W. Schleif, L. Gabryelski, 2007, Bioorganic & medicinal chemistry letters.

Synthesis of a Series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4- dihydroquinazolin-2(1H)-ones as Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

W. M. Sanders, P. Anderson, W. Schleif, 1994 .

Structure and activity of hydrogenated derivatives of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801).

J. Kemp, D. Middlemiss, T. Lyle, 1990, Journal of medicinal chemistry.